Search clinical trials for: Immunotherapy treatment

Total 66382 results

Maria Sklodowska-Curie National Research Institute...
Immutep S.A.S.

Recruiting

Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial (EFTISARC-NEO)

Immunotherapy | Sarcoma,Soft Tissue | Radiation Therapy | Neoadjuvant

Poland
Tang-Du Hospital

Recruiting

Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer

Gastric Cancer

China
Ruijin Hospital

Recruiting

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Peking University First Hospital

Recruiting

Adjuvant Radiotherapy and Combined Adjuvant Treatment Strategy for UTUC

Urothelial Carcinoma

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Locally Advanced Rectal Cancer - a Multicenter, Single-arm, Open-label Clinical Trail

Locally Advanced Rectal Adenocarcinoma
Sun Yat-sen University

Not yet recruiting

Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy

Colorectal Cancer
National Cancer Institute (NCI)

Recruiting

Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma

United States
UNICANCER
SOLTI Breast Cancer Research Group; Vall d'Hebron Institute of Oncology; MSD...

Not yet recruiting

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC (ETNA)

Triple-negative Breast Cancer
GlaxoSmithKline
iTeos Therapeutics

Recruiting

Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Neoplasms, Head and Neck

United States, Italy, Spain, Taiwan, Germany, Greece, Korea, Republic of, Romania, Sweden, Turkey, Canada, Argentina, Finland, Brazil, Japan, Poland, Portugal, France, Denmark, Hungary, Norway
CatalYm GmbH

Recruiting

Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer

Adult Solid Tumor | Bladder Cancer

Italy
National Cancer Institute (NCI)

Recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Hormone Receptor-Positive Breast Carcinoma | HER2-Negative Breast Carcinoma

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer (RCT-PAAG)

Pancreatic Adenocarcinoma Metastatic

China
University of Saskatchewan

Not yet recruiting

Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer

Liver Metastasis Colon Cancer
Cancer Research UK
Aleta BioTherapeutics

Recruiting

A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

Lymphoma, Follicular | Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell

United Kingdom
Zhejiang Cancer Hospital

Not yet recruiting

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Non-small Cell Lung Cancer Stage III
National Cancer Institute (NCI)

Recruiting

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma

United States, Hong Kong
General Administration of Military Health, Tunisia

Recruiting

e-ITAG Allergen Immunotherapy in the Management of Allergic Asthma (EITAG)

Study the Efficacy of ITA in Patients With Allergic Asthma or Allergic Rhinitis or Allergic Rhinitis Compared With Conventional Treatment

Tunisia
National Cancer Institute (NCI)

Recruiting

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study

Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 | Muscle Invasive Bladder Urothelial Carcinoma

United States
Fudan University

Recruiting

Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

HER2-positive Gastric Cancer | Immunotherapy

China
Zhongshan People's Hospital, Guangdong, China

Recruiting

Anrotinib and Tirelizumab in First-line Treatment of RM-NPC

Nasopharyngeal Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC (NeoR-World)

Non-Small Cell Lung Cancer

China
University of Malaya

Recruiting

Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma

Advanced Solid Tumor | Pancreatic Ductal Adenocarcinoma

Malaysia
Antonio Pérez Martínez

Recruiting

Clinical Trial of Infusion of Activated NK Cells for the Treatment of Sarcomas (SANKOMA)

Malignant Sarcoma

Spain
Shanghai Chest Hospital

Recruiting

Molecular Analysis and Treatment Options of SCLC

Small Cell Lung Carcinoma | Small-cell Lung Cancer | Small Cell Lung Cancer Limited Stage | Small Cell Lung Cancer Extensive Stage | Small Cell Lung Cancer, Combined Type

China
Peking Union Medical College Hospital

Recruiting

Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Biliary Tract Neoplasms | Immunotherapy

China
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Early Stage Triple-Negative Breast Carcinoma

United States, Puerto Rico
Istituti Clinici Scientifici Maugeri SpA
Merck Sharp & Dohme LLC

Not yet recruiting

Pembrolizumab in Locally Advanced Sinonasal Carcinoma (NeoPeSino)

Sinonasal Undifferentiated Carcinoma

Italy
Renmin Hospital of Wuhan University

Recruiting

A Study of Chemoradiation in Combination With Tislelizumab as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Xinqiao Hospital of Chongqing

Not yet recruiting

Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer

NSCLC | Radiotherapy | Immunotherapy | Intensity Modulated Radiation Therapy
Hirva Mamdani
AstraZeneca; Barbara Ann Karmanos Cancer Institute

Recruiting

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer (MOZART)

Small Cell Lung Cancer | SCLC | Extensive Stage Small Cell Lung Cancer

United States
Second Affiliated Hospital of Zunyi Medical University
Guizhou Provincial People's Hospital; The First People's Hospital of Zunyi; Guizhou... and other collaborators

Recruiting

Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC

Immunotherapy | Second-line Treatment

China
Erasmus Medical Center

Recruiting

TEIPP Immunotherapy in Patients With NSCLC (TEIPP)

Non Small Cell Lung Cancer

Netherlands
Nielsen BioSciences, Inc.

Recruiting

Candin for the Treatment of Common Warts

Common Warts (Verruca Vulgaris)

United States
Shanghai Yunying Medical Technology
The PLA Navy Anqing Hospital

Recruiting

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors

Sarcoma | Breast Cancer | Head and Neck Cancer | Small Cell Lung Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Lung Cancer | Non Small Cell Lung Cancer | Liver Cancer | Bronchial Cancer

China
Shanghai Yunying Medical Technology
The Affiliated Hospital of Xuzhou Medical University

Recruiting

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors

Sarcoma | Carcinoma | Breast Cancer | Gynecologic Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Liver Cancer

China
Shanghai Yunying Medical Technology
Xi'an Honghui Hospital

Recruiting

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors

Sarcoma | Osteosarcoma | Sarcoma,Soft Tissue | Bone Tumor

China
National Cancer Institute (NCI)

Recruiting

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Gastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Gastroesophageal Junction Adenocarcinoma | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric... and other conditions

United States
Fujian Medical University Union Hospital

Not yet recruiting

Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer

Immunotherapy;Envafolimab; Esophageal Cancer
RenJi Hospital
The First Affiliated Hospital with Nanjing Medical University; Peking University... and other collaborators

Recruiting

Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

China
Shanghai Yunying Medical Technology
Shanghai 10th People's Hospital

Recruiting

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer

Cervical Cancer | Endometrial Cancer | Advanced Cancer

China
Centre Hospitalier Universitaire, Amiens
Central Hospital Saint Quentin

Recruiting

Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment (Ibe2i-TIPCI)

Immunotherapy | Immune Checkpoint Inhibitors | Immune-related Adverse Event | Predictive Biomarkers

France
Shanghai Yunying Medical Technology
Shanghai 10th People's Hospital

Recruiting

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Carcinomatosis

China
M.D. Anderson Cancer Center
Cancer Cures 4 Kids

Recruiting

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

Angiosarcoma

United States
Xijing Hospital

Not yet recruiting

An Exploratory Study of Immunotherapy Combined With Anlotinib and Chemotherapy in Perioperative Treatment of LAGC

Gastric Cancer

China
Xuzhou Medical University

Recruiting

A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom

Lung Squamous Cell Carcinoma

China
Fudan University

Recruiting

Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)

Non-small Cell Lung Cancer | Neoadjuvant Therapy | Immunotherapy | Stage II-IIIA

China
National Health Research Institutes, Taiwan
National Cheng-Kung University Hospital

Recruiting

Neoantigen Derived DCs as Cancer Treatment

Solid Tumor | Refractory Tumor

Taiwan
University Hospital, Antwerp
Roche Pharma AG; Algemeen Ziekenhuis Maria Middelares; Kom Op Tegen Kanker; Vitaz

Recruiting

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma (Immuno-MESODEC)

Malignant Pleural Mesothelioma

Belgium
Zagazig University

Recruiting

Human Papilloma Virus Genotypes and Treatment Outcomes of Intralesional Immunotherapy of Anogenital Warts

Human Papilloma Virus | Anogenital Wart

Egypt
Wuxi People's Hospital

Not yet recruiting

A Clinical Study on the Efficacy and Mechanism of Tumor Treatment Vaccine (TTV) for Recurrent and Refractory Advanced Solid Tumors

Solid Tumors, Adult

Search clinical trials for: Immunotherapy treatment

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations